CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Clinical trial NCT03123783 · COMPLETED

Trial details

NCT number: NCT03123783
Sponsor: Apexigen America, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cancer Non Small Cell Lung Cancer Metastatic Metastatic Melanoma Neoplasm of Lung Melanoma

Start date: 2017-07-10
Primary completion: 2020-11-16
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.